27665747|t|Upregulation and activation of δ ‑opioid receptors p romotes the progression of human b reast cancer
27665747|a|δ‑opioid receptor (DOR) belongs to the family of G protein‑coupled receptors (GPCRs). Numerous studies have shown that DOR is widely distributed in human peripheral tissues and is closely related to the development and progression of certain malignant tumours. However, there is controversy in the literature regarding whether DOR has an impact on the development and progression of human breast cancer. The present study comprehensively elaborates on the biological functions of DOR by determining the distribution of DOR expression in breast cancer tissues and cells and by further verifying the effects of DOR on breast cancer progression. DOR was found to be highly expressed in human breast cancer tissues and cells. In addition, the high expression level of DOR positively correlated with tumour grade and clinical stage and negatively correlated with breast cancer metastasis and prognosis. Upregulating and activating DOR promoted the proliferation of human breast cancer cells in a concentration‑dependent manner within a specific concentration range, whereas downregulating or inhibiting DOR activation significantly suppressed cell proliferation. The majority of tumour cells were arrested in G1 phase, and some cells exhibited apoptosis. DOR upregulation and activation induced protein kinase C (PKC) activation, resulting in increased phosphorylation levels of extracellular signal‑regulated kinases (ERKs). After inhibition of the P KC /ERK signalling pathway, the effects of DOR on breast cancer were significantly attenuated in vivo and in vitro. In summary, DOR is highly expressed in breast cancer and is closely related to its progression. These results suggest that DOR may serve as a potential biomarker for the early diagnosis of breast cancer and may be a viable molecular target for therapeutic intervention.
27665747	0	12	Upregulation	T044	C0949479
27665747	17	27	activation	T043	C1514758
27665747	33	52	‑opioid receptors p	T116,T192	C0140057
27665747	65	76	progression	T046	C1947901
27665747	80	85	human	T016	C0086418
27665747	88	100	reast cancer	T191	C0006142
27665747	101	118	δ‑opioid receptor	T116,T192	C0140057
27665747	120	123	DOR	T116,T192	C0140057
27665747	152	177	protein‑coupled receptors	T116,T192	C0682972
27665747	179	184	GPCRs	T116,T192	C0682972
27665747	220	223	DOR	T116,T192	C0140057
27665747	249	254	human	T016	C0086418
27665747	255	273	peripheral tissues	T024	C0040300
27665747	304	315	development	T039	C0243107
27665747	320	331	progression	T046	C1947901
27665747	343	360	malignant tumours	T191	C0006826
27665747	428	431	DOR	T116,T192	C0140057
27665747	453	464	development	T039	C0243107
27665747	469	480	progression	T046	C1947901
27665747	484	489	human	T016	C0086418
27665747	490	503	breast cancer	T191	C0006142
27665747	517	522	study	T062	C2603343
27665747	523	538	comprehensively	T080	C1880156
27665747	557	577	biological functions	T038	C3714634
27665747	581	584	DOR	T116,T192	C0140057
27665747	604	616	distribution	T169	C1704711
27665747	620	623	DOR	T116,T192	C0140057
27665747	624	634	expression	T045	C0597360
27665747	638	651	breast cancer	T191	C0006142
27665747	652	659	tissues	T024	C0040300
27665747	664	669	cells	T025	C0334227
27665747	699	709	effects of	T080	C1704420
27665747	710	713	DOR	T116,T192	C0140057
27665747	717	730	breast cancer	T191	C0006142
27665747	731	742	progression	T046	C1947901
27665747	744	747	DOR	T116,T192	C0140057
27665747	771	780	expressed	T045	C0597360
27665747	784	789	human	T016	C0086418
27665747	790	803	breast cancer	T191	C0006142
27665747	804	811	tissues	T024	C0040300
27665747	816	821	cells	T025	C0334227
27665747	845	861	expression level	T081	C3244092
27665747	865	868	DOR	T116,T192	C0140057
27665747	869	879	positively	T033	C1514241
27665747	896	908	tumour grade	T080	C0475753
27665747	913	927	clinical stage	T201	C1300072
27665747	932	942	negatively	T033	C1513916
27665747	959	972	breast cancer	T191	C0006142
27665747	973	983	metastasis	T046	C4255448
27665747	988	997	prognosis	T201	C1516221
27665747	999	1011	Upregulating	T044	C0949479
27665747	1016	1026	activating	T043	C1514758
27665747	1027	1030	DOR	T116,T192	C0140057
27665747	1044	1057	proliferation	T043	C0596290
27665747	1061	1066	human	T016	C0086418
27665747	1067	1080	breast cancer	T191	C0006142
27665747	1081	1086	cells	T025	C0334227
27665747	1170	1184	downregulating	T044	C0013081
27665747	1188	1198	inhibiting	T052	C3463820
27665747	1199	1202	DOR	T116,T192	C0140057
27665747	1203	1213	activation	T043	C1514758
27665747	1228	1238	suppressed	T169	C1260953
27665747	1239	1257	cell proliferation	T043	C0596290
27665747	1275	1287	tumour cells	T025	C0334227
27665747	1293	1301	arrested	T043	C1155873
27665747	1305	1313	G1 phase	T079	C0079395
27665747	1324	1329	cells	T025	C0334227
27665747	1340	1349	apoptosis	T043	C0162638
27665747	1351	1354	DOR	T116,T192	C0140057
27665747	1355	1367	upregulation	T044	C0949479
27665747	1372	1382	activation	T043	C1514758
27665747	1391	1407	protein kinase C	T116,T126	C1259877
27665747	1409	1412	PKC	T116,T126	C1259877
27665747	1414	1424	activation	T045	C0599177
27665747	1449	1464	phosphorylation	T044	C0031715
27665747	1465	1471	levels	T080	C0441889
27665747	1475	1513	extracellular signal‑regulated kinases	T116,T126	C0600388
27665747	1515	1519	ERKs	T116,T126	C0600388
27665747	1546	1550	P KC	T116,T126	C1259877
27665747	1548	1574	KC /ERK signalling pathway	T044	C0037080
27665747	1580	1590	effects of	T080	C1704420
27665747	1591	1594	DOR	T116,T192	C0140057
27665747	1598	1611	breast cancer	T191	C0006142
27665747	1642	1649	in vivo	T082	C1515655
27665747	1654	1662	in vitro	T080	C1533691
27665747	1667	1674	summary	T170	C0242482
27665747	1676	1679	DOR	T116,T192	C0140057
27665747	1690	1699	expressed	T045	C0597360
27665747	1703	1716	breast cancer	T191	C0006142
27665747	1747	1758	progression	T046	C1947901
27665747	1766	1773	results	T169	C1274040
27665747	1787	1790	DOR	T116,T192	C0140057
27665747	1806	1815	potential	T080	C3245505
27665747	1816	1825	biomarker	T201	C0005516
27665747	1834	1839	early	T079	C1279919
27665747	1840	1849	diagnosis	T033	C0011900
27665747	1853	1866	breast cancer	T191	C0006142
27665747	1887	1903	molecular target	T104,T120	C1513403
27665747	1908	1932	therapeutic intervention	T061	C0808232